Inosine Pranobex — Is a Single Positive Trial Enough?

Abstract

Recognition of the myriad immunologic defects associated with human immunodeficiency virus (HIV) infection has stimulated the development of novel approaches to its treatment. To date, the most effective treatments have been antiviral agents directed against HIV itself, such as zidovudine (formerly AZT, or azidothymidine). However, active efforts continue in the search for agents to restore or improve the defective immune systems of persons infected with HIV. Although the distinction between immunomodulatory and antiretroviral therapy is not always clear, the possibility of a combined approach is conceptually exciting. The clinical testing of potential immunomodulators increases the complexity of drug development by . . .